Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: An open-label, single-dose, phase i study

Clinical Therapeutics

Volumn 36, Issue 5, 2014, Pages 722-736

  Clarke, Bart L ^a   Kay Berg, Jolene ^b   Fox, John ^c   Cyran, Jane A ^c   Lagast, Hjalmar ^c  

^a MAYO CLINIC   (United States)

^b PRACS Institute   (United States)

^c NPS Pharmaceuticals Inc   (United States)

Author keywords

calcium; hypoparathyroidism; parathyroid hormone; pharmacokinetics; phosphate; rhPTH(1 84)

Indexed keywords

CALCITRIOL; CALCIUM; CREATININE; CYCLIC AMP; MAGNESIUM; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT PARATHYROID HORMONE; VITAMIN D;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CYCLIC AMP URINE LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DYSMENORRHEA; FEMALE; GOUT; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPARATHYROIDISM; INJECTION SITE BLEEDING; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE HEMATOMA; MUSCLE STRAIN; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHASE 1 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; SINGLE DRUG DOSE; TACHYPNEA; TIME TO MAXIMUM PLASMA CONCENTRATION; VAGINA BLEEDING; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; HORMONE SUBSTITUTION; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPARATHYROIDISM; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PARATHYROID HORMONE; VITAMIN D;

EID: 84901455066     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.04.001     Document Type: Article

References (28)

1. National Organization for Rare Disorders. Hypoparathyroidism. http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/703/ viewAbstract. Accessed January 21, 2014.
2. T. Bohrer Permanent postoperative hypoparathyroidism. An epidemiological clinical study using a new questionnaire instrument J Ukrainian Acad Sci 9 2003 476 494
3. J.T. Potts Jr Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders D.L. Kasper, Harrison's Principles of Internal Medicine. Vol 16 2005 McGraw-Hill New York, NY 2249 2268
4. J.P. Bilezikian, A. Khan, and J.T. Potts Jr et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research J Bone Miner Res 26 2011 2317 2337
5. M.I. Khan, S.G. Waguespack, and M.I. Hu Medical management of postsurgical hypoparathyroidism Endocr Pract 17 Suppl 1 2011 18 25
6. D. Shoback Clinical practice. Hypoparathyroidism N Engl J Med 359 2008 391 403
7. D.M. Mitchell, S. Regan, and M.R. Cooley et al. Long-term follow-up of patients with hypoparathyroidism J Clin Endocrinol Metab 97 2012 4507 4514
8. M.J. Horwitz, and A.F. Stewart Hypoparathyroidism: is it time for replacement therapy? J Clin Endocrinol Metab 93 2008 3307 3309
9. K.K. Winer, C.W. Ko, and J.C. Reynolds et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium J Clin Endocrinol Metab 88 2003 4214 4220
10. K.K. Winer, J.A. Yanovski, B. Sarani, and G.B. Cutler Jr A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism J Clin Endocrinol Metab 83 1998 3480 3486
11. K.K. Winer, B. Zhang, and J.A. Shrader et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism J Clin Endocrinol Metab 97 2012 391 399
12. M.R. Rubin, J. Sliney Jr, and D.J. McMahon et al. Therapy of hypoparathyroidism with intact parathyroid hormone Osteoporos Int 21 2010 1927 1934
13. T. Sikjaer, L. Rejnmark, and L. Rolighed et al. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study J Bone Miner Res 26 2011 2358 2370
14. M. Mannstadt, B.L. Clarke, and T. Vokes et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomized, Phase 3 study Lancet Diabetes Endocrinol 1 2013 275 283
15. N.E. Cusano, M.R. Rubin, and D.J. McMahon et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety J Clin Endocrinol Metab 98 2013 137 144
16. Fox J, Wells DS, Garceau RJ. Relationships between pharmacokinetic profile of human PTH (1-84) and serum calcium response in postmenopausal women following four different methods of administration. http://www.asbmr.org/ Meetings/AnnualMeeting/AbstractDetail.aspx?aid=cb1c7954-4672-41f1-8b55- 9a70ec107b6f. Accessed January 21, 2014.
17. H.L. Henry, R.J. Midgett, and A.W. Norman Regulation of 25-hydroxyvitamin D3-1-hydroxylase in vivo J Biol Chem 249 1974 7584 7592
18. H.L. Henry, and A.W. Norman Studies on calciferol metabolism. IX. Renal 25-hydroxy-vitamin D3-1 hydroxylase. Involvement of cytochrome P-450 and other properties J Biol Chem 249 1974 7529 7535
19. D.M. Shoback, M. Mannstadt, and B.L. Clarke et al. The effect of recombinant human parathyroid hormone (rhPTH[1-84]) on vitamin D metabolism: results from phase III REPLACE and phase I clinical studies Endocr Rev 34 03-MeetingAbstracts 2013 (SUN-234)
20. B.L. Clarke, D.M. Shoback, and M. Mannstadt et al. The effect of recombinant human parathyroid hormone (rhPTH[1-84]) on phosphate homeostasis in patients with hypoparathyroidism Endocr Rev 34 03-MeetingAbstracts 2013 (SUN-246).
21. G.A. Block Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients Clin Nephrol 54 2000 318 324
22. K.R. Scott, and J. Fox Comparison of hypotensive response following intravenous injection of parathyroid hormone 1-84 and 1-34 in conscious rats Calcif Tissue Int 79 2006 389 394
23. B. Jespersen, A. Randlov, and J. Abrahamsen et al. Effects of PTH(1-34) on blood pressure, renal function, and hormones in essential hypertension: the altered pattern of reactivity may counteract raised blood pressure Am J Hypertens 10 1997 1356 1367
24. A.E. Broadus, J.E. Mahaffey, F.C. Bartter, and R.M. Neer Nephrogenous cyclic adenosine monophosphate as a parathyroid function test J Clin Invest 60 1977 771 783
25. H. Heath 3rd, and D.C. Purnell Urinary cyclic 3',5'-adenosine monophosphate responses to exogenous and endogenous parathyroid hormone in familial benign hypercalcemia and primary hyperparathyroidism J Lab Clin Med 96 1980 974 984
26. D.M. Antoniucci, D.E. Sellmeyer, and J.P. Bilezikian et al. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis J Clin Endocrinol Metab 92 2007 942 947
27. D.C. Bauer, P. Garnero, and J.P. Bilezikian et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis J Clin Endocrinol Metab 91 2006 1370 1375
28. D.E. Sellmeyer, D.M. Black, and L. Palermo et al. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis Osteoporos Int 18 2007 973 979